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Background/aim: We aimed to investigate and compare to healthy controls the variations in the levels of nitric oxide (NO), asymmetric
dimethyl arginine (ADMA), symmetric dimethyl arginine (SDMA), and L-arginine levels in patients with obsessive-compulsive
disorder (OCD).
Materials and methods: We enrolled 30 patients with OCD and 30 healthy controls in the study consecutively. Diagnostic interviews
of all participants were conducted with the Structured Clinical Interview for Axis I Disorders (SCID-I), and sociodemographic data of
the participants were recorded. Patients scoring 10 points or more on the Yale–Brown Obsessive-Compulsive Scale were enrolled in the
study.
Results: The NO levels of patients with OCD were increased compared to the control group, but the increase was not statistically
significant (P > 0.05). However, patients with OCD had significantly lower levels of ADMA, SDMA, and L-arginine compared with the
controls (P < 0.001).
Conclusion: We found a significant decrease in ADMA, SDMA, and L-arginine as NO inhibitors between the groups, possibly because
of an increase in NO. However, the insignificant increase in NO suggests that ADMA, SDMA, and L-arginine play direct and potentially
important roles in OCD biology.
Key words: Obsessive-compulsive disorder, nitric oxide, asymmetric dimethyl arginine, symmetric dimethyl arginine, L-arginine

1. Introduction
Obsessive-compulsive disorder (OCD) is a psychiatric
disorder of unknown etiology with a prevalence of 1.9%–
3.3% and a usually chronic trend that can significantly
impair patients’ quality of life (1). It is known that the
oxidative mechanisms in OCD are unbalanced, but at the
same time, nitric oxide (NO) level can be an important
factor in OCD biology (2,3).
Synthesized by the nitric oxide synthase (NOS)
enzyme from the L-arginine amino acid, NO is a lipophilic
compound with a very short half-life, small molecular
structure, and key functions. LN-monomethyl arginine
(L-NMMA), symmetric dimethyl arginine (SDMA),
and asymmetric dimethyl arginine (ADMA), as natural
analogs of the L-arginine amino acid, may competitively
* Correspondence: enveryilmaz6@yahoo.com.tr

inhibit NO synthesis. The neuronal NOS (nNOS)
enzyme undertaking NO synthesis is found at higher
concentrations in the cerebellum, cerebral cortex, and
cerebral areas associated with anxiety and memory such as
the hypothalamus, hippocampus, and amygdala (4).
According to a few studies, NO is effective in brain
development and realization of brain function (5,6). In
addition to the release of noradrenaline and dopamine, NO
plays a role in the regulation of numerous physiological
functions such as memory and learning, regulation of
nociceptive sensory neurons, balance, transmission of
stimuli, smelling, and eating (7,8). In addition to affecting
various enzyme activities and neurotransmitter release
and reuptake in neuropsychiatric diseases, NO plays a
role in many physiological and pathological phenomena
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such as regulation of the cerebrovascular system, cerebral
ischemia, paralysis, pain perception, cerebral damage
related to alcohol consumption, and neurotoxicity in
Alzheimer and Huntington diseases (9,10).
The results of a few clinical and experimental studies
suggest that NO, which has important biological activity
in the central nervous system (CNS) and its periphery, and
it may have a role in psychiatric disorders such as alcohol
and drug addiction, schizophrenia, mood disorders,
and OCD (11,12). Another study reported that neurons
regulating nNOS release in suprachiasmatic nuclei in the
CNS are reduced by 40% in depression, NMDA receptors
effective in NO synthesis play an important role in anxiety
and affective disorders, and NMDA receptor antagonist
treatments have effective anxiolytic and antidepressant
efficacy (13).
Most studies pertaining to NO inhibitors in the
literature employed ADMA. ADMA is a natural amino
acid present in cells and tissues; it can circulate freely
in the plasma and it is removed from the body via
urination. Because it is a natural NOS inhibitor, ADMA
as a molecule has been addressed significantly in various
studies (14). According to previous reports, ADMA may
serve as a mortality indicator in cardiovascular diseases.
Furthermore, it may be associated with coronary heart
diseases and hypercholesterolemia, as well as stroke and
ischemic attacks in cerebrovascular diseases (15). ADMA
levels increase and NO levels decrease in major depression
(13). Moreover, some studies have indicated that various
NOS-inhibiting agents generate antidepressant effects
in laboratory animals (16,17). Ferreira et al. observed
that 7-nitroindazole, a central selective NOS inhibitor,
potentiates the anxiolytic effects of alcohol in experimental
anxiety created in rats (18). The anxiolytic effects of NOS
inhibitors are supported by other studies as well (19).
Our literature review revealed no study collectively
addressing the relationship between NO and its inhibitors,
namely ADMA, SDMA, and L-arginine, in OCD. Based
on the assumption that in OCD neurobiology there may
be differences among NO levels and ADMA, SDMA, and
L-arginine levels, which are natural NO inhibitors, it is
aimed to investigate the roles of NO, ADMA, SDMA, and
L-arginine levels in OCD.
2. Materials and methods
2.1. Participants
The Ethics Committee of the Faculty of Medicine of Fırat
University approved the study. All participants were
informed about the study, and blood samples were taken
with their informed consent.
Thirty inpatient and outpatient OCD patients (13 males,
17 females) admitted to the Istanbul Erenköy Training and
Research Hospital for Mental and Neurological Diseases
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during April–June 2010 and 30 healthy controls (12 males,
18 females) were sequentially included as participants in
the study. Diagnostic interviews of all participants were
conducted according to the Diagnostic and Statistical
Manual of Psychiatry 4th version (DSM IV) Structured
Clinical Interview for Axis I Disorders (SCID-I) (20),
and the sociodemographic data of the participants were
recorded.
Criteria for inclusion in the study were as follows:
1) Patient age greater than 18 years
2) Clinically diagnosed with OCD as per the DSM-IV
3) Ten or more points on the Yale–Brown ObsessiveCompulsive Scale
4) Reading and signing the informed consent form
Criteria for exclusion in the study were as follows:
1) Patient age less than 18 years
2) Currently diagnosed with psychiatric disorders other
than OCD
3) Currently having a cardiovascular disease
4) Currently having a cerebrovascular disease
5) Diagnosed with diabetes mellitus
6) Having defects in renal functions
2.2. Clinical scales
2.2.1. Structured Clinical Interview for DSM-IV Axis I
Disorders (SCID-I)
This interview was developed in 1987 to diagnose subjects/
patients according to the DSM III-R criteria, followed by
DSM-IV adaptation in 1997 (20). A validity and reliability
study of its Turkish form was performed (21).
2.2.2. Yale–Brown Obsessive-Compulsive Rating Scale
(Y-BOCS)
Goodman et al. developed this scale for clinicians to rate
the severity of obsessive-compulsive symptoms (22).
Items 1–5 on the scale reflect obsession points, and items
6–10 reflect compulsion points. The sum of both types of
points yields the total obsessive-compulsive score. Two
independent studies have tested the validity and reliability
of the Turkish form of this scale (23,24).
2.3. Biochemical measurements
We took 4 mL of fasting blood samples from each participant
by venipuncture after 12 h of fasting, between 0800 and
0900 hours, and collected the samples in anticoagulant-free
vacuum tubes. The samples were allowed to clot and then
centrifuged at 3000 × g for 10–15 min. The serum aliquots
were stored at –80 °C until we assayed and thawed them
immediately before the measurement of the biochemical
parameters. Routine biochemical parameters and lipid
levels were measured in an autoanalyzer with appropriate
commercial kits (Abbot Brand kits and Abbott Architect
C8200I, Abbott Corp., USA).
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2.3.1. Measuring total nitric oxide (NOX) levels of the
serum
Nitric oxide produced in biological systems is oxidized
into nitrite (NO2) and nitrate (NO3) in a very short period
of 2–30 s. Therefore, by measuring NO2 and NO3 levels, we
determined the total nitric oxide levels.
We authors employed a spectrophotometric
method modified by Cortas et al. (25) for NO2 and NO3
measurements.
2.3.2. Measuring serum arginine, ADMA, and SDMA
In this study, L-arginine, ADMA, and SDMA levels were
measured by high-performance liquid chromatography
(HPLC) using a EUREKA kit (EUREKA, Italy) and a
fluorescence detector (26).
2.4. Statistical analysis
The data collected in the study are presented as average ±
standard deviation. For comparisons between groups, we
applied Student’s t-test, the chi-square test, and Fischer’s
exact chi-square test with P < 0.05 as the lowest significance
level.

3. Results
The sociodemographic data related to the groups are
presented in Table 1. In Table 1, we summarize the
results of a comparison of age made using Student’s t-test
and those of the other parameters using chi-square and
Fischer’s exact chi-square tests.
The biochemical parameters of both groups were
compared with Student’s t-test and no significant difference
was found between the control group and the OCD group
in terms of glucose, urea, and creatinine levels (P > 0.05, P
> 0.05, P > 0.05) (Table 2).
In contrast, based on the respective lipid parameters
of the groups, total cholesterol values were significantly
higher in the OCD patient group compared to the control
group (P < 0.05). Moreover, triglyceride values were found
to be significantly different between the groups (P < 0.05)
(Table 2).
An increase in NO level (51.58 ± 8.30 µmol/L) was
observed in the control group compared to that (54.01 ±
6.52 µmol/L) in the OCD group, not reflecting a statistically
significant difference (P > 0.05).

Table 1. Sociodemographic data of control and OCD patient groups (Student’s t-test, chi-square test, Fischer’s exact
test).
Groups

P

Control (n = 30)

OCD (n = 30)

Age (years)

35.19 ± 9.99

33.26 ± 10.38

NS

Sex (M / F)

12 / 18

13 / 17

NS

Not literate

-

1

Primary school

6

6

Secondary school - high school

15

19

University

9

4

Married

22

14

Single

8

16

Provincial center

18

26

District

6

3

Village or town

1

1

Yes

27

14

No

3

16

Yes

-

5

No

30

25

Y-BOCS score

0.00 ± 00

21.53 ± 5.25

Educational status

P < 0.05

Marital status
P < 0.05

Residence
NS

Status of employment
P < 0.001

History of disease in the family
P < 0.001
P < 0.001

OCD: Obsessive-Compulsive disorder, Y-BOCS: Yale–Brown Obsessive-Compulsive Rating Scale, NS: not significant.
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Table 2. Biochemical parameters of control and OCD patient groups (Student’s t-test).
Groups

P

Control (n = 30)

OCD (n = 30)

Glucose (mg/dL)

91.61 ± 7.96

98.06 ± 9.68

P < 0.05

Urea (mg/dL)

28.00 ± 6.37

27.41 ± 5.37

P > 0.05

Creatinine (mg/dL)

0.78 ± 0.09

0.81 ± 0.13

P > 0.05

Total cholesterol (mg/dL)

166.94 ± 17.07

186.83 ± 44.98

P < 0.05

Triglyceride (mg/dL)

86.00 ± 22.64

115.81 ± 59.38

P < 0.05

HDL (mg/dL)

47.96 ± 12.22

47.66 ± 12.78

P > 0.05

LDL (mg/dL)

101.31 ± 18.03

118.16 ± 38.96

P < 0.05

NO (µmol/L)

51.58 ± 8.30

54.01 ± 6.52

P > 0.05

L - Arginine (µmol/L)

74.75 ± 9.19

45.74 ± 9.42

P < 0.001

ADMA (µmol/L)

5.72 ± 1.81

2.31 ± 0.59

P < 0.001

SDMA (µmol/L)

3.67 ± 0.98

0.27 ± 0.06

P < 0.001

OCD: Obsessive-compulsive disorder, HDL: high-density lipoprotein, LDL: low-density lipoprotein, NO: nitric oxide,
ADMA: asymmetric dimethyl arginine, SDMA: symmetric dimethyl arginine.

A comparison of serum L-arginine level in the OCD
group (45.74 ± 9.42 µmol/L) with that in the control
group (74.75 ± 9.19 µmol/L) revealed a highly significant
decrease in patients with OCD (P < 0.001).
In contrast, the level of serum ADMA, a natural NOS
inhibitor in NO metabolism, decreased significantly in the
OCD group (2.31 ± 0.59 µmol/L) compared to the control
group (5.72 ± 1.81 µmol/L) (P < 0.001).
The average SDMA level of 0.27 ± 0.06 µmol/L in the
OCD group was significantly lower than the value of 3.67
± 0.98 µmol/L in the control group (P < 0.001).
4. Discussion
According to a few studies, in several neuropsychiatric
disorders, free oxygen radicals effectively influence disease
onset and prognosis, as well as changes occurring in blood
circulation of brain (15,27). NO’s role in CNS-related
diseases is believed to be mediated by an excessive release
mechanism (28,29).
In the present study, which is the first to collectively
investigate the levels of NO, ADMA, SDMA, and
L-arginine, we found that NO level was insignificantly
higher in patients with OCD compared to the control
group, while ADMA, SDMA, and L-arginine levels were
significantly lower.
The findings in the literature indicate that as ADMA
level increases, NO level decreases (10,30,31). In our
study, although NO level was determined to increase,
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the increase was not statistically significant. This finding
might result from the fact that the sample group was not
large enough. In addition, Zincir and Zincir (32) claimed
that abnormalities in NO and ADMA production in
schizophrenia patients can be related to disease chronicity.
Similarly, abnormalities in the production of NO and
ADMA in OCD patients can vary with the chronicity of
OCD.
In recent years, free oxygen radicals have come to
be known as a risk factor in pathogenesis and systemic
complications of many diseases, including neuropsychiatric
disorders, and many studies have attempted to inhibit and
treat cell damage caused by free oxygen radicals (33,34).
NO is a neuromodulator highly addressed in recent
psychiatry studies (34–36). Symptoms caused by neuronal
damage associated with changes in NO levels in the CNS
have attracted increased research attention toward the
role of NO metabolism in diseases causing psychiatric
disorders. Here, in addition to the relationship of NO with
cerebral regions known to be associated with a variety of
symptoms and mental disorders, NO is known to play a
critical role in combination with a few structures to give
rise to neuronal damage (28). Moreover, a few compounds,
which are natural NO inhibitors, released in an organism
with NO may play a role in this condition. ADMA,
SDMA, and L-arginine are the most important examples
of such compounds (37). In combination with free oxygen
radicals, NO forms highly toxic peroxynitrite radicals
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that cause destruction, particularly by damaging cell
membranes (38). Because of reactions with heavy metals,
severe cellular damage may occur from lipid peroxidation
and nitrosylation of various molecules (39).
Studies report that changes in NO levels play
an important role in conditions such as behavioral
development, changes in appetite, and disorders such as
brachial ischemia, schizophrenia and bipolar disorders,
depression, and eating disorders (4,32,40,41).
The authors of an investigation of NO levels in bipolar
disorders found higher NO levels in patients compared
to the control group (42). Another study proved that the
average plasma ADMA concentration in schizophrenia
patients is 3 times higher than that in healthy subjects
(43). Two separate studies found higher NO levels in
patients with depression compared to those in the control
groups (44,45). Yet another study found lower NO levels in
patients compared with the control group (46). In a study
performed on a control group composed of 21 pregnant
women with depression and 42 participants, lower plasma
levels of ADMA and L-arginine as NO inhibitors were
found in pregnant women with depression (47). In studies
measuring NO levels on cerebellar Purkinje fiber synapses
in rats under depression, the authors reported that
changes in NO levels were associated with psychomotor
failure (48,49). One study showed that fluoxetine and
tianeptine as antidepressant agents inhibit nNOS in the
CNS to suppress NO activity (50). In one study where NO,
nesfatin-1, and ghrelin levels were investigated in patients
with major depression after venlafaxine treatment,
posttreatment nesfatin-1 and ghrelin levels decreased
significantly, contrary to the NO level, which increased
significantly. The findings of that study suggest that
decreasing nesfatin-1 and increasing NO towards normal
values constitutes a major criterion in the evaluation of
treatment response (51).
In a study of Alzheimer patients, the increase in ADMA
levels in the plasma and the decrease in ADMA levels in
the cerebrospinal fluid were highly significant (52). In
another study, ADMA eased the response to acetylcholine
by affecting cerebral blood flow in the resting condition
(37).
In a study, it was found that NO level was higher in
OCD patients compared to that in controls, and the authors
of that study stated that NO might be an important factor
in OCD biology (3). In our study, NO level was found to
be insignificantly higher in the patient group compared
to that in the control group. The higher NO level in OCD
patients compared to that in the controls might be ascribed
to the fact that in the mentioned study, plasma NO levels
were studied, whereas we investigated NO levels in serum
samples. In addition, we thing that this difference could
be due to the difference in case numbers in both studies.

Increase in the levels of NO as an antioxidant may be in
response to a pathology in OCD biology. However, despite
the insignificant increase in NO levels, we found highly
significant increases in the levels of ADMA, SDMA, and
L-arginine as NO inhibitors between the groups. Although
a possible interpretation is that an increase in NO led to
a decrease in inhibitors, the insignificant increase in NO
suggests direct, potentially important roles of ADMA,
SDMA, and L-arginine in NO biology. Our review of
the literature reveals that these findings have not been
reported hitherto in OCD patients. Moreover, according
to the literature, increase in NO level, despite it being an
antioxidant, may have direct neurotoxic effects (53,54).
It is known that ADMA increases oxidative stress,
especially causing damage in lipid levels and weakening
the enzymatic antioxidant system (55,56). According to a
study on metabolic syndrome (MS) patients, fluvastatine
given to cure the disorders in the lipid profile causes
recovery in the lipid profile while causing a significant
decrease in serum ADMA levels, and, in this way, it is
effective on endothelial functions in MS patients (57,58).
In our study, when considering the lipid parameters
together with increased ADMA levels in OCD patients, we
observed that there were significant increases, especially
in LDL cholesterol and triglyceride levels. According the
literature, an increase in ADMA levels increases vascular
risk factors, especially in patients with coronary heart
disease (59). Lundman et al. also reported that ADMA
levels increased significantly together with the increase
in triglyceride levels (60). This shows that the increase
in ADMA levels, especially abnormalities in lipid levels
together with irregularities in NO metabolism resulting
from vascular structure dysfunction, can be more risky
for OCD patients with regard to cardiovascular and
cerebrovascular complications. In the etiopathogenesis of
OCD patients, complex mechanisms are effective, in which
free radicals are also held responsible for, in addition to
serum ADMA levels and abnormalities in lipid levels, risk
factors that play important roles in endothelial structure
degeneration. Therefore, to prevent cardiovascular and
cerebrovascular system complications, new treatment
approaches effective on these parameters should be
developed.
There are some limitations to our study. In addition to
the limited number of participants, several publications
in the literature suggest that a few metabolic disorders,
insulin resistance, glucose tolerance, diabetes mellitus,
hyperlipidemia, chronic kidney disease, hypertension, and
coronary heart diseases may be associated with increased
ADMA levels (61,62). Moreover, in this study, we found
that total cholesterol and triglyceride levels in OCD
patients were higher compared to those in the control
group, but there was no difference between the groups
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in terms of blood glucose, urea, and creatinine levels. In
addition, most of our patients were medicated with SSRI
group antidepressants. Data from the literature suggest
that antidepressant agents are effective for oxidative stress
and NO (63,64).
All these data indicate the need to carry out further
studies on the relationship among NO, ADMA, SDMA,

and L-arginine in OCD neurobiology with greater
numbers of participants to obtain deeper statistics.
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